newswire.com /1 month ago

Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia

Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia followi...

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Onswik for Adults with Type 2 Diabetes ]]>

Read source
pharmexec.com /1 month ago

<![CDATA[ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care]]>

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Related searches